DaVita Inc
DVA: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$262.00 | Lgfychr | Nvqgbsskr |
DaVita Facing Near-Term Challenges, but Long-Term Prospects Remain Solid
Business Strategy and Outlook
After selling the DaVita Medical Group in 2019, DaVita focuses almost exclusively on providing services to end-stage renal disease, or ESRD, patients primarily in the United States with an expanding international footprint. Over several decades, DaVita has built the largest network of dialysis clinics in the U.S., and although COVID-19-related mortality concerns look likely to constrain results through 2022, we view DaVita's long-term prospects as solid.